# Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders

> **NCT00846547** · PHASE2 · COMPLETED · sponsor: **Seaside Therapeutics, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Autism Spectrum Disorders

## Interventions

- **DRUG:** Arbaclofen

## Key facts

- **NCT ID:** NCT00846547
- **Lead sponsor:** Seaside Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2010-06
- **Final completion:** 2010-09
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00846547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00846547, "Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00846547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*